



# Rheumatology Grand Rounds

*Presented by*

**Section of Rheumatology, Allergy & Immunology**

## “Special Considerations of Anti-Rheumatic Drugs in the Days of Biologics”

**David N. Podell, MD, PhD, ACP, FACR**

Chairman, Department of Medicine, Waterbury Hospital  
Clinical Professor of Medicine, Yale University School of Medicine and Frank H. Netter School of Medicine

**Date: Wednesday, December 9, 2020**

**Time: 8:00-9:00 am**

**ZOOM-**<https://zoom.us/j/92058054060?pwd=M285RlJ3TmgwOG03ZVY2VkkxZNktNZz09&from=addon>

**Via phone – Dial Meeting ID:**

CME: To record your attendance to this activity,  
text the Activity Code, 20683 to 203-442-9435 from 7:45am-9:15am

**Course Director/Host: Fotios Koumpouras, MD**

*There is no corporate support for this activity*

This course will fulfill the licensure requirement set forth by the State of Connecticut

### **ACCREDITATION**

The Yale School of Medicine is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

### **TARGET AUDIENCE**

Department faculty, attending physicians, subspecialty fellows, community physicians, resident house staff, physician assistants and medical students.

### **NEEDS ASSESSMENT**

Rheumatoid Arthritis can be a debilitating disease affecting not only the joints but other organ systems causing limiting ones quality of life. Rheumatoid Arthritis has a multitude of medications including biologics which have revolutionized the treatment for RA patients. It is important to be aware of special considerations of these medications given the complexity of some of our patients. We will discuss some new discoveries with the help of understanding this crucial topic in Rheumatology with case-based clinical scenarios.

### **LEARNING OBJECTIVES**

At the conclusion of this activity, participants will be able to:

1. To review the special considerations of new biologic and other anti-rheumatic drugs
2. To review some of the newer recent discoveries pertinent to rheumatic diseases

3. To discuss case based clinical scenarios of challenging patients with rheumatic diseases

### **DESIGNATION STATEMENT**

The Yale School of Medicine designates this live activity for 1 AMA PRA Category 1 Credit(s)<sup>™</sup>. Physicians should only claim the credit commensurate with the extent of their participation in the activity.

### **FACULTY DISCLOSURES**

*Speaker:* David Podell, MD, PhD – NONE

*Course Director:* Fotios Koumpouras, MD- Celgene (honorarium), Aurora (research grant), EMD, ULB, GSK (research grant)

It is the policy of Yale School of Medicine, Continuing Medical Education, to ensure balance, independence, objectivity and scientific rigor in all its educational programs. All faculty participating as speakers in these programs are required to disclose any relevant financial relationship(s) they (or spouse or partner) have with a commercial interest that benefits the individual in any financial amount that has occurred within the past 12 months; and the opportunity to affect the content of CME about the products or services of the commercial interests. The Center for Continuing Medical Education will ensure that any conflicts of interest are resolved before the educational activity occurs.